Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15787560 | 0.86 | NOS3 (0.41) | TAAR1NOS3NOS1NOS2RAPGEF4 | |
| SCHEMBL537203 | 0.84 | TAAR1 (0.60) | TAAR1CYP1A2CYP2A6NOS3NOS1 | |
| SCHEMBL3849051 | 0.84 | TAAR1 (0.60) | TAAR1CYP1A2CYP2A6NOS3NOS1 | |
| SCHEMBL1014548 | 0.84 | TAAR1 (0.60) | TAAR1CYP2A6MAOBHTR2AHTR2C | |
| SCHEMBL31614540 | 0.82 | LOXL2 (0.42) | TAAR1NOS3NOS1NOS2MAOB | |
| SCHEMBL4162524 | 0.82 | LOXL2 (0.42) | TAAR1NOS3NOS1NOS2MAOB | |
| Hydrochloric Acid SCHEMBL5151143 | 0.81 | TAAR1 (0.58) | TAAR1CYP1A2CYP2A6NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL2211247 | 0.81 | TAAR1 (0.58) | TAAR1CYP2A6MAOBHTR2AHTR2C | |
| SCHEMBL16958903 | 0.80 | FFAR4 (0.39) | NOS3NOS1NOS2RAPGEF4 | |
| SCHEMBL16953464 | 0.78 | RAPGEF4 (0.35) | NOS3NOS1NOS2RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-09-28 | — | — | US | disclosed |
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1767525-A1 | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1385823-B1 | GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS | CHIRON CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6960582-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050038027-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2005-02-17 | — | — | US | disclosed |
| EP-1385823-A4 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORP (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040248895-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2004-12-09 | — | — | US | disclosed |
| US-6716840-B2 | AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES | CHIRON CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040024211-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385823-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020193595-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002081443-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038027-A1 | Novel guanidino compounds | MC4R, MC3R, GCKR | TAAR1 1637/4885CYP1A2 3224/4885CYP2A6 2902/4885 |
| US-20040024211-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | TAAR1 220/4885CYP1A2 2672/4885CYP2A6 1609/4885 |
| US-20020193595-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | TAAR1 251/4885CYP1A2 3041/4885CYP2A6 2233/4885 |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | TAAR1 2977/4885CYP1A2 346/4885CYP2A6 511/4885 |
| US-20040248895-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | TAAR1 211/4885CYP1A2 2335/4885CYP2A6 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.